Disappointing results for mesothelioma immunotherapy trial 

Data from the highly anticipated PROMISE-meso trial failed to deliver, with no PFS or OS benefit seen for pembrolizumab compared to standard chemotherapy. The Phase III trial involved 144 patients with advanced pre-treated mesothelioma who were randomised to pembrolizumab (200 mg every three weeks) or chemotherapy (gemcitabine/vinorelbine). Patients in the control group were able to ...